| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Regentis Biomaterials Ltd.$3.79
+0.15 (+4.12%)
F 10Pipeline Score MedTech · Pre-Clinical
Market Cap
11.45 M
EPS
-2.67
P/E Ratio
-
Value Trade
39.50 K
11.06 %
Week
-27.3 %
1 Month
-43.48 %
3 Month
-70.14 %
6 Month
-70.14 %
5 Year
-70.14 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
83.60 K
52 Week Range
1.82 - 8.35
% held by Insiders
52.02 %
% held by Institutions
16.38 %
Enterprise Value
5.27 M
Total Shares
5.18 M
Short %
6.8 %
Float Shares
2.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 839 of 911)
Percentile RankRegentis Biomaterials Ltd. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GelrinC | knee cartilage repair | Phase 3 | 2026-01-20 | 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage; MRI findings revealed progressive improvement in tissue organization over time; By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilage Read More | Regentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method Read More | |
GelrinC | knee cartilage repair | Phase 3 | 2026-01-20 | 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage; MRI findings revealed progressive improvement in tissue organization over time; By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilage Read More | Regentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method Read More | |
GelrinC | knee cartilage repair | Phase 3 | 2026-01-20 | 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage; MRI findings revealed progressive improvement in tissue organization over time; By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilage Read More | Regentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RGNT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RGNT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RGNT▼ -22.1%on this news
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement HERZLIYA, IL
Regentis Biomaterials Ltd. has announced a private placement aimed at raising $6.5 million through the issuance of ordinary shares and warrants. The company plans to use the proceeds to support its pivotal clinical trial for GelrinC and advance regulatory submissions, including activities for FDA approval. GelrinC is an innovative hydrogel for knee cartilage repair that has already received CE Mark approval in the EU. The placement is expected to close around June 23, 2026, pending customary closing conditions.
Read more →RGNTRegentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate GelrinC , positioned as the first off-the-shelf cell-free hydrogel implant for knee cartila
Regentis Biomaterials Ltd. is preparing to commence European surgeon training for GelrinC, its innovative cell-free hydrogel implant for knee cartilage repair, having received CE Mark approval. The training aims to equip orthopedic surgeons with hands-on experience using GelrinC, which is designed to streamline the 10-minute implantation process. This initiative signifies a critical step towards commercialization in a competitive $3 billion market, where traditional solutions have been prevalent. Clinical data suggest GelrinC provides enhanced recovery outcomes, and Regentis aims to foster confidence and support among surgeons through a network of Centers of Excellence across Europe.
Read more →RGNTNOTICE OF AN ANNUAL GENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON THURSDAY, JULY 2, 2026 To the shareholders of Regentis Biomaterials Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of t
Regentis Biomaterials Ltd. has scheduled its Annual General Meeting for July 2, 2026, in Tel Aviv, Israel. The meeting will address several key agenda items, including the re-elections of directors, approval of options grants, and the adoption of the company's Compensation Policy. Shareholders as of June 9, 2026, will be entitled to vote and participate in discussions concerning financial statements and other business matters. The Board of Directors advises shareholders to vote in favor of all proposed items.
Read more →RGNT▲ +8.1%on this news
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update $7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA
Regentis Biomaterials reported its 2025 financial results and provided a business update, announcing $7.4 million in cash to support site expansion and patient enrollment for its pivotal Phase III trial of GelrinC. GelrinC is already approved in Europe and is slated for rollout in 2026, aiming to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repair. Despite these advancements, the company noted a going concern qualification in its audit report, emphasizing the importance of upcoming trial outcomes and financial health.
Read more →RGNT▼ -10.5%on this news
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026 New clinical sites to support engagemen
Regentis Biomaterials has announced the expansion of its European clinical site network, strategically increasing its presence in key markets like Italy and Eastern Europe. This move supports its ongoing pivotal Phase III clinical trials in conjunction with the commercial launch of GelrinC, which has already received CE Mark approval for knee cartilage repair. The expansion aims to deepen engagement with orthopedic surgeons and facilitate broader clinical adoption, enhancing Regentis' commercial strategy ahead of its targeted launch in 2026.
Read more →RGNT▼ -17.1%on this news
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
Regentis Biomaterials has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. His experience is expected to aid the company's transition towards commercialization of GelrinC, a hydrogel implant for knee cartilage repair. GelrinC has received CE Mark approval in Europe and is currently undergoing a pivotal Phase III trial in the U.S.
Read more →RGNTRegentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
Regentis Biomaterials has expanded its U.S. clinical site network for the pivotal Phase III study of GelrinC, a hydrogel for knee cartilage repair. The addition of leading orthopedic centers aims to accelerate patient enrollment and enhance clinical data generation. GelrinC is already approved in the EU and targets a significant U.S. market.
Read more →RGNTRegentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
Regentis Biomaterials has announced promising long-term results from its GelrinC treatment for knee cartilage repair. MRI data shows that patients treated with GelrinC exhibit cartilage structures resembling healthy native tissue, indicating true biological regeneration. This innovative hydrogel limits fibrotic tissue overgrowth and supports natural joint biomechanics, enhancing the potential for durable joint function.
Read more →RGNTRegentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a
Regentis Biomaterials announced that their product GelrinC has shown long-term durability in cartilage repair using MOCART, a quantitative evaluation method published in a peer-reviewed journal. The results indicate that two years post-treatment, cartilage regeneration closely resembles healthy cartilage, thus positioning GelrinC as a leader in cartilage repair solutions. The Phase II clinical trial was conducted with oversight from Vienna University and highlights GelrinC's competitive edge against other treatment options. Currently, GelrinC is undergoing a pivotal Phase III trial in the U.S., with enrollment surpassing 50%.
Read more →RGNTRegentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeon
Regentis Biomaterials announced the issuance of a new U.S. patent for its regenerative cartilage repair product, GelrinC. This patent protects the ready-to-use liquid formulation that improves surgical efficiency by enabling a quicker procedure. GelrinC, which has already gained CE Mark approval in the EU, is currently undergoing a pivotal FDA trial and has surpassed 50% enrollment. The product offers a promising solution for knee cartilage repair, backed by a robust intellectual property portfolio.
Read more →RGNTRegentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Regentis Biomaterials Ltd. has successfully closed its initial public offering, raising $10 million by selling 1,250,000 ordinary shares at $8.00 each. The shares commenced trading on the NYSE American under the ticker RGNT. The company plans to utilize the proceeds for development activities, including a pivotal trial for its lead product, GelrinC.
Read more →RGNTRegentis Biomaterials Ltd. Announces Pricing of Initial Public Offering Herzliya, Israel
Regentis Biomaterials Ltd. has announced the pricing of its initial public offering, setting the price at $8.00 per share for a total of $10 million in gross proceeds. The company will utilize the funds primarily for development activities related to its lead product, GelrinC, which is aimed at treating knee cartilage injuries. Ordinary shares are expected to begin trading on the NYSE American under the ticker RGNT on December 4, 2025. The offering also allows underwriters a 45-day option to purchase additional shares for over-allotments.
Read more →Competitive Position
How RGNT ranks across every disease it competes inCompetitive Position is a premium feature
See how RGNT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial